Categories
- Aesthetic Medicine
- Aesthetic Surgery
- Ai
- ALS Treatment
- Anatomy
- Artificial General Intelligence
- Artificial Intelligence
- Batten Disease Treatment
- BioEngineering
- BioInformatics
- Biology
- Biotechnology
- Bitcoin
- Brain Injury Treatment
- Cardiac Nursing
- Cardiac Regeneration
- Cardiac Remodeling
- Cardiac Rhythm Abnormalities
- Cardiac Surgery
- Cardiology
- Cardiomyopathies
- Cardiovascular Pharmacology
- Cell Medicine
- Cell Therapy
- Cerebral Palsy
- Cerebral Palsy Treatment
- Cheap Pharmacy
- Chemistry
- Clinical Cardiology
- Coronary Heart Diseases
- Cryptocurrency
- DNA
- Drug Dependency
- Drug Side Effects
- Drugs
- Eczema
- Elon Musk
- Embryology
- Erectile Dysfunction
- FDA Stem Cell Trials
- Femtomedicine
- Future Medicine
- Gene Medicine
- Gene Therapy
- Gene Therapy Trials
- Genetic Engineering
- Genetic Therapy
- Genetics
- Germ Line Engineering
- Heart Diseases
- HGH
- Hgh Injections
- Hormone Replacement Therapy
- Human Genetics
- Human Growth Hormone
- Human Immortality
- Hyperbaric Medicine
- Hypertension
- Hypothalamus
- Impotency
- Internet Pharmacy
- Interventional Cardiology
- IVF Treatment
- Lyme Disease
- Male Sexual Dysfunction
- Mars Colony
- Medical Business
- Medical School
- Medical Technology
- Medicine
- Mental Health
- Mesenchymal Stem Cells
- Micropenia
- Molecular Cardiology
- MS Treatment
- Muscular Dystrophy Treatment
- Myocardial Infarction
- Nanotechnology
- Online Pharmacy
- Oral Health
- Parkinson's Treatment
- Pediatric Cardiology
- Penis Enlargement
- Pet Stem Cell Therapy
- Pharmacy
- Picomedicine
- Premature Ejaculation
- Prescriptions
- Retinitis Pigmentosa
- Sermorelin
- Singularity
- Sleep
- Spacex
- Spinal Cord Injury Treatment
- Stem Cell Clinical Trials
- Stem Cell Experiments
- Stem Cell Human Trials
- Stem Cell Injections
- Stem Cell Research
- Stem Cell Transplant
- Stem Cell Treatments
- Testosterone
- Ulcerative Colitis
- Uncategorized
- Vascular Biology
- Ventricular Remodeling
- Wholesale Pharmacy
Archives
Search Results for: hans keirstead spinal cord injury
Treatment for Spinal Cord Injury To Start Clinical Trial …
Posted: Published on March 23rd, 2018
San Francisco, CA Asterias Biotherapeutics Inc. has been given approval by the Food and Drug Administration (FDA) to begin a clinical trial of its stem cell therapy in patients with spinal cord injury. The California Institute for Regenerative Medicine (CIRM), Californias stem cell agency, is funding the trial. The Phase 1/2a clinical trial is designed to test the safety of this approach and to see if it has any benefit for patients. The trial will use increasing doses of Asterias AST-OPC1 cells. These are a form of cell called oligodendrocyte progenitor, which are capable of becoming several different kinds of cells some of which play a supporting role and help protect nerve cells in the central nervous system, the area damaged in spinal cord injury. The trial is a follow-on to the CIRM-funded clinical trial begun by Geron in 2010 using the same kind of stem cell. Geron halted that clinical trial due to a change in business strategy. At the time five patients had been treated with the AST-OPC1 cells. Since then follow-up studies on the five patients have shown no serious side effects due to the therapy and in four of the five patients, MRI scans have shown … Continue reading
Posted in Spinal Cord Injury Treatment
Comments Off on Treatment for Spinal Cord Injury To Start Clinical Trial …
Spinal Cord Injury Fact Sheet | California’s Stem Cell Agency
Posted: Published on March 15th, 2018
CIRM funds many projects seeking to better understand spinal cord injury and to translate those discoveries into new therapies. About 250,000 people in the U.S. live with spinal cord injuries. Half of those are quadriplegic, with the paralysis impacting all four limbs to some extent. For those individuals the lifetime cost of managing their condition is estimated to be between $2 million and $3 million. Spinal cord injury became the first condition targeted in a human clinical trial using cells made from embryonic stem cells. That trial, begun by Geron in 2010 and based on the findings of a team CIRM currently funds, was later cancelled by Geron for financial reasons. By the time of the cancellation five patients around the country had been enrolled in the study, including two at Stanford, who entered the trial during a period when CIRM funded Geron. Those patients continue to be followed to learn as much as possible about this approach. Californias stem cell agency retains many grants for research to move potential spinal cord injury therapies forward (the full list is below). Much of this work focuses on trying to determine which type of nerve cell is the best one to transplant, … Continue reading
Posted in Spinal Cord Injury Treatment
Comments Off on Spinal Cord Injury Fact Sheet | California’s Stem Cell Agency
Hans Keirstead- Stem Cells Restore Mobility in Neck-Injured Rats (UC Irvine) – Video
Posted: Published on November 1st, 2012
Hans Keirstead- Stem Cells Restore Mobility in Neck-Injured Rats (UC Irvine) Download: savedmy.com Stem cells have the potential to treat a wide range of diseases, but developing those cures is a process that has many hurdles. Dr. Hans Kierstead has a CIRM grant to develop a treatment for spinal cord injury. He is co-director of the Sue and Bill Gross Stem Cell Research Center and associate professor of anatomy and neurobiology at the University of California, Irvine.From:Grablampet2Views:244 0ratingsTime:02:36More inGaming The rest is here: Hans Keirstead- Stem Cells Restore Mobility in Neck-Injured Rats (UC Irvine) - Video … Continue reading
Posted in Stem Cell Human Trials
Comments Off on Hans Keirstead- Stem Cells Restore Mobility in Neck-Injured Rats (UC Irvine) – Video
Hans Keirstead: Developing therapies based on embryonic stem cells – Video
Posted: Published on October 14th, 2011
Stem cells have the potential to treat a wide range of diseases, but developing those cures is a process that has many hurdles. Dr. Hans Kierstead has a CIRM grant to develop a treatment for spinal cord injury Original post: Hans Keirstead: Developing therapies based on embryonic stem cells - Video … Continue reading
Posted in FDA Stem Cell Trials
Comments Off on Hans Keirstead: Developing therapies based on embryonic stem cells – Video
Embryonic stem cell – Wikipedia
Posted: Published on November 2nd, 2018
Embryonic stem cells (ES cells or ESCs) are pluripotent stem cells derived from the inner cell mass of a blastocyst, an early-stage pre-implantation embryo.[1][2] Human embryos reach the blastocyst stage 45 days post fertilization, at which time they consist of 50150 cells. Isolating the embryoblast, or inner cell mass (ICM) results in destruction of the blastocyst, a process which raises ethical issues, including whether or not embryos at the pre-implantation stage should have the same moral considerations as embryos in the post-implantation stage of development.[3][4] Researchers are currently focusing heavily on the therapeutic potential of embryonic stem cells, with clinical use being the goal for many labs.[5] Potential uses include the treatment of diabetes and heart disease.[5] The cells are being studied to be used as clinical therapies, models of genetic disorders, and cellular/DNA repair. However, adverse effects in the research and clinical processes such as tumours and unwanted immune responses have also been reported.[6] Embryonic stem cells (ESCs), derived from the blastocyst stage of early mammalian embryos, are distinguished by their ability to differentiate into any cell type and by their ability to propagate. It is these traits that makes them valuable in the scientific/medical fields. ESC are also … Continue reading
Posted in Stem Cell Research
Comments Off on Embryonic stem cell – Wikipedia
He broke ground in stem-cell research. Now he’s running for Congress. – Washington Post
Posted: Published on June 20th, 2017
The small pack of scientists running for political office has grown by one. Stem-cell researcher Hans Keirstead, 50, announced last week that he will try to unseat Californias Rep. Dana Rohrabacher (R). Keirstead, a Democrat with a PhD in neuroscience from the University of British Columbia, was a professor at the University of California at Irvinebefore launching and selling several biotech companies. Rohrabacher, who represents the 48th District in Southern California, has been in Congress since 1988. Democrats there see 2018 asa vulnerable year for the incumbent. Although Republicans outnumber Democrats in thedistrict, Hillary Clinton swung it in the 2016 election. And Rohrabacher has come under scrutiny for his support of acloser relationship with Russia. In May, the chair of Orange County Democrats toldThe Washington Post that challengers were coming out the woodwork to oppose him. Five candidatesbesides Keirstead have declared they are running for the seat. Keirstead emerged from academic and entrepreneurial fields. Hepioneered a technique to purify stem cells You cant go putting toenails into the spinal cord, he said and applied this method to spinal-cord injuries and diseases such ascancer and amyotrophic lateral sclerosis, or ALS. In 2014,he sold a stem-cell company in a deal reportedly worth … Continue reading
Posted in Stem Cell Research
Comments Off on He broke ground in stem-cell research. Now he’s running for Congress. – Washington Post
Stem cell scientist to become the latest Democrat trying to topple Dana Rohrabacher in OC House race – Los Angeles Times
Posted: Published on June 15th, 2017
An internationally known stem cell scientist and entrepreneur will join the ranks of candidates trying to unseat Republican incumbents in contested House races next year when he announces Thursday his challenge of 18-term Rep. Dana Rohrabacher. Hans Keirstead, a 50-year-old Democrat from Laguna Beach, said Wednesday that he will run in the 48th Congressional District, one of more than half a dozen in California that have been targeted by Democrats seeking to harness sentiment against President Trump in their fight for a House majority. Keirsteads candidacy has been sought by some national Democratic figures, who see his science and business background as a good fit for the district. It runs along the Orange County coastline from Laguna Beach to Seal Beach, and includes some nearby inland cities. Republicans represent a plurality of the district with more than 40% of its registration, to about 30% for Democrats. A quarter of voters are registered as nonpartisan. The Huntington Beach-based Rohrabacher, who is 69, has served in the House since 1988. Part of the reason for the Democratic drought in the 48th and other districts now seen as competitive has been the partys candidates; Rohrabacher last faced a serious challenge in 2008, when … Continue reading
Posted in Stem Cell Research
Comments Off on Stem cell scientist to become the latest Democrat trying to topple Dana Rohrabacher in OC House race – Los Angeles Times
Human embryonic stem cells clinical trials – Wikipedia …
Posted: Published on October 24th, 2015
Human Embryonic Stem Cell Clinical Trials[edit] Introduction[edit] The Food and Drug Administration (FDA) approved the first clinical trial in the United States involving human embryonic stem cells on January 23, 2009. Geron Corporation, a biotechnology firm located in Menlo Park, California, originally planned to enroll ten patients suffering from spinal cord injuries to participate in the trial. The company hoped that GRNOPC1, a product derived from human embryonic stem cells, would stimulate nerve growth in patients with debilitating damage to the spinal cord.[1] The trial began in 2010 after being delayed by the FDA because cysts were found on mice injected with these cells, and safety concerns were raised.[2] In the United States, the FDA must approve all clinical trials involving newly developed pharmaceuticals. Researchers must complete an Investigational New Drug (IND) application in order to earn the FDAs approval. IND applications typically include data from animal and toxicology studies in which the drugs safety is tested, drug manufacturing information explaining how and where the drug will be produced, and a detailed research protocol stating who will be included in the study, how the drug will be administered and how participants will be consented.[3] Testing for new drugs must successfully … Continue reading
Posted in FDA Stem Cell Trials
Comments Off on Human embryonic stem cells clinical trials – Wikipedia …
CSC Announces FDA Approval Of Phase II Cancer Stem Cell …
Posted: Published on March 7th, 2014
IRVINE, Calif. (February 18, 2014) California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Companys application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer. The randomized, double-blind study is the Companys second cancer therapy approved for clinical trials by FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The Companys patient-specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer. Led by Chief Medical Officer Robert Dillman, M.D., the study design randomizes an estimated 99 adult female patients to two treatment arms. The treatment group will receive Ovapuldencel-T, which is a combination of autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF. Ovapuldencel-T is created by first isolating cancer stem cells from the patients resected tumor sample, then enriching, inactivating and combining these cells with dendritic cells or antigen-presenting immune cells which are harvested from the patients blood. The control group will receive the MC treatment, harvested … Continue reading
Posted in FDA Stem Cell Trials
Comments Off on CSC Announces FDA Approval Of Phase II Cancer Stem Cell …
California Stem Cell Announces U.S. FDA Approval of Phase …
Posted: Published on February 23rd, 2014
IRVINE, Calif.--(BUSINESS WIRE)--California Stem Cell, Inc. (CSC) announced today that the U.S. Food and Drug Administration (FDA) has approved the Companys application to begin a Phase II clinical trial exploring the potential of a patient-specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer. The randomized, double-blind study is the Companys second cancer therapy approved for clinical trials by the FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The Companys patient-specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer. Led by Chief Medical Officer Robert Dillman, M.D., the study design randomizes an estimated 99 adult female patients to two treatment arms. The treatment group will receive Ovapuldencel-T, which is a combination of autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF. Ovapuldencel-T is created by first isolating cancer stem cells from the patient's resected tumor sample, then enriching, inactivating and combining these cells with dendritic cells or antigen-presenting immune cells which are harvested from the patients blood. The control group will receive the MC treatment, harvested from the … Continue reading
Posted in FDA Stem Cell Trials
Comments Off on California Stem Cell Announces U.S. FDA Approval of Phase …